In vitro antibacterial activity of at-2266 and its therapeutic efficacy on respiratory tract infections

Seiichi Aonuma, Kikuo Onuma, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno, Kosaku Nagai

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Recently, a new oral antimicrobial agent, structurally related to nalidixic acid, was synthesized in laboratory of Dainippon Pharmaceutical Co. Ltd. in Japan. It was shown that this new agent possessed a broad antimicrobial spectrum covering gram-positive cocci and gram-negative bacilli. Minimal inhibitory concentrations (MICs) of the agent against each 20 clinical isolates of S. aureus, E. coli, K. pneumoniae, S. marcescens, E. cloacae and P. aeruginosa were determined by use of Dynatech MIC 2000 system. At a concentration of 0.78μg/ml, this agent inhibited 65, 85, 95, 90, 80 and 70% of the strains of S. aureus, E.coli, K. pneumoniae, S. marcescens, E. cloacae and P. aeruginosa, respectively. Nine patients suffering from respiratory tract infections received orally 600 mg of the drug a day. Seven showed a good response and two a fair response. No undesirable symptoms and signs due to administration of the drug were observed. No abnormality in laboratory findings was noted during and after the treatment with the drug.

    Original languageEnglish
    Pages (from-to)385-390
    Number of pages6
    JournalChemotherapy
    Volume32
    Issue numberSupplement
    DOIs
    Publication statusPublished - 1984 Jan

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'In vitro antibacterial activity of at-2266 and its therapeutic efficacy on respiratory tract infections'. Together they form a unique fingerprint.

    Cite this